494 related articles for article (PubMed ID: 22960785)
1. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.
Rolland M; Edlefsen PT; Larsen BB; Tovanabutra S; Sanders-Buell E; Hertz T; deCamp AC; Carrico C; Menis S; Magaret CA; Ahmed H; Juraska M; Chen L; Konopa P; Nariya S; Stoddard JN; Wong K; Zhao H; Deng W; Maust BS; Bose M; Howell S; Bates A; Lazzaro M; O'Sullivan A; Lei E; Bradfield A; Ibitamuno G; Assawadarachai V; O'Connell RJ; deSouza MS; Nitayaphan S; Rerks-Ngarm S; Robb ML; McLellan JS; Georgiev I; Kwong PD; Carlson JM; Michael NL; Schief WR; Gilbert PB; Mullins JI; Kim JH
Nature; 2012 Oct; 490(7420):417-20. PubMed ID: 22960785
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.
Edlefsen PT; Rolland M; Hertz T; Tovanabutra S; Gartland AJ; deCamp AC; Magaret CA; Ahmed H; Gottardo R; Juraska M; McCoy C; Larsen BB; Sanders-Buell E; Carrico C; Menis S; Kijak GH; Bose M; ; Arroyo MA; O'Connell RJ; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Rerks-Ngarm S; Robb ML; Kirys T; Georgiev IS; Kwong PD; Scheffler K; Pond SL; Carlson JM; Michael NL; Schief WR; Mullins JI; Kim JH; Gilbert PB
PLoS Comput Biol; 2015 Feb; 11(2):e1003973. PubMed ID: 25646817
[TBL] [Abstract][Full Text] [Related]
3. Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
Gartland AJ; Li S; McNevin J; Tomaras GD; Gottardo R; Janes H; Fong Y; Morris D; Geraghty DE; Kijak GH; Edlefsen PT; Frahm N; Larsen BB; Tovanabutra S; Sanders-Buell E; deCamp AC; Magaret CA; Ahmed H; Goodridge JP; Chen L; Konopa P; Nariya S; Stoddard JN; Wong K; Zhao H; Deng W; Maust BS; Bose M; Howell S; Bates A; Lazzaro M; O'Sullivan A; Lei E; Bradfield A; Ibitamuno G; Assawadarachai V; O'Connell RJ; deSouza MS; Nitayaphan S; Rerks-Ngarm S; Robb ML; Sidney J; Sette A; Zolla-Pazner S; Montefiori D; McElrath MJ; Mullins JI; Kim JH; Gilbert PB; Hertz T
J Virol; 2014 Aug; 88(15):8242-55. PubMed ID: 24829343
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.
Pollara J; Bonsignori M; Moody MA; Liu P; Alam SM; Hwang KK; Gurley TC; Kozink DM; Armand LC; Marshall DJ; Whitesides JF; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; O'Connell RJ; Kim JH; Michael NL; Montefiori DC; Tomaras GD; Liao HX; Haynes BF; Ferrari G
J Virol; 2014 Jul; 88(14):7715-26. PubMed ID: 24807721
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens.
Karnasuta C; Akapirat S; Madnote S; Savadsuk H; Puangkaew J; Rittiroongrad S; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Tartaglia J; Sinangil F; Francis DP; Robb ML; de Souza MS; Michael NL; Excler JL; Kim JH; O'Connell RJ; Karasavvas N
AIDS Res Hum Retroviruses; 2017 May; 33(5):410-423. PubMed ID: 28006952
[TBL] [Abstract][Full Text] [Related]
6. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
7. HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.
Easterhoff D; Pollara J; Luo K; Janus B; Gohain N; Williams LD; Tay MZ; Monroe A; Peachman K; Choe M; Min S; Lusso P; Zhang P; Go EP; Desaire H; Bonsignori M; Hwang KK; Beck C; Kakalis M; O'Connell RJ; Vasan S; Kim JH; Michael NL; Excler JL; Robb ML; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Nitayaphan S; Sinangil F; Tartaglia J; Phogat S; Wiehe K; Saunders KO; Montefiori DC; Tomaras GD; Moody MA; Arthos J; Rao M; Joyce MG; Ofek G; Ferrari G; Haynes BF
JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996483
[TBL] [Abstract][Full Text] [Related]
8. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
9. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
10. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.
Rao M; Peachman KK; Kim J; Gao G; Alving CR; Michael NL; Rao VB
Curr HIV Res; 2013 Jul; 11(5):427-38. PubMed ID: 24191938
[TBL] [Abstract][Full Text] [Related]
12. Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.
Mielke D; Stanfield-Oakley S; Borate B; Fisher LH; Faircloth K; Tuyishime M; Greene K; Gao H; Williamson C; Morris L; Ochsenbauer C; Tomaras G; Haynes BF; Montefiori D; Pollara J; deCamp AC; Ferrari G
J Virol; 2022 Jan; 96(2):e0164321. PubMed ID: 34730393
[TBL] [Abstract][Full Text] [Related]
13. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
Karasavvas N; Billings E; Rao M; Williams C; Zolla-Pazner S; Bailer RT; Koup RA; Madnote S; Arworn D; Shen X; Tomaras GD; Currier JR; Jiang M; Magaret C; Andrews C; Gottardo R; Gilbert P; Cardozo TJ; Rerks-Ngarm S; Nitayaphan S; Pitisuttithum P; Kaewkungwal J; Paris R; Greene K; Gao H; Gurunathan S; Tartaglia J; Sinangil F; Korber BT; Montefiori DC; Mascola JR; Robb ML; Haynes BF; Ngauy V; Michael NL; Kim JH; de Souza MS;
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1444-57. PubMed ID: 23035746
[TBL] [Abstract][Full Text] [Related]
14. Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.
Spurrier B; Sampson J; Gorny MK; Zolla-Pazner S; Kong XP
J Virol; 2014 Apr; 88(8):4100-12. PubMed ID: 24478429
[TBL] [Abstract][Full Text] [Related]
15. RV144 HIV-1 vaccination impacts post-infection antibody responses.
Mdluli T; Jian N; Slike B; Paquin-Proulx D; Donofrio G; Alrubayyi A; Gift S; Grande R; Bryson M; Lee A; Dussupt V; Mendez-Riveria L; Sanders-Buell E; Chenine AL; Tran U; Li Y; Brown E; Edlefsen PT; O'Connell R; Gilbert P; Nitayaphan S; Pitisuttihum P; Rerks-Ngarm S; Robb ML; Gramzinski R; Alter G; Tovanabutra S; Georgiev IS; Ackerman ME; Polonis VR; Vasan S; Michael NL; Kim JH; Eller MA; Krebs SJ; Rolland M
PLoS Pathog; 2020 Dec; 16(12):e1009101. PubMed ID: 33290394
[TBL] [Abstract][Full Text] [Related]
16. Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
Cram JA; Fiore-Gartland AJ; Srinivasan S; Karuna S; Pantaleo G; Tomaras GD; Fredricks DN; Kublin JG
PLoS One; 2019; 14(12):e0225622. PubMed ID: 31869338
[TBL] [Abstract][Full Text] [Related]
17. CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants.
Dommaraju K; Kijak G; Carlson JM; Larsen BB; Tovanabutra S; Geraghty DE; Deng W; Maust BS; Edlefsen PT; Sanders-Buell E; Ratto-Kim S; deSouza MS; Rerks-Ngarm S; Nitayaphan S; Pitisuttihum P; Kaewkungwal J; O'Connell RJ; Robb ML; Michael NL; Mullins JI; Kim JH; Rolland M
PLoS One; 2014; 9(10):e111334. PubMed ID: 25350851
[TBL] [Abstract][Full Text] [Related]
18. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
Front Immunol; 2020; 11():719. PubMed ID: 32411138
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
[TBL] [Abstract][Full Text] [Related]
20. Novel directions in HIV-1 vaccines revealed from clinical trials.
Excler JL; Tomaras GD; Russell ND
Curr Opin HIV AIDS; 2013 Sep; 8(5):421-31. PubMed ID: 23743791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
